New Data at AAN Showcase Biogen’s Commitment to Advancing Innovation in MS
Patients treated with VUMERITY® (diroximel fumarate) and TECFIDERA® (dimethyl fumarate) showed a significant reduction of gadolinium-enhancing lesions compared to baseline Additional data show improved gastrointestinal tolerability with VUMERITY compared …